Puma Biotechnology (PBYI) Aktievy
Puma Biotechnology, Inc. är ett biofarmaceutiskt företag som fokuserar på utveckling och kommersialisering av produkter för att förbättra cancervården i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 2/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
PBYI Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Puma Biotechnology, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$7.08 |
| 52 veckors högsta | US$7.90 |
| 52 veckors lägsta | US$3.03 |
| Beta | 1.23 |
| 1 månads förändring | -6.10% |
| 3 månaders förändring | -0.42% |
| 1 års förändring | 118.86% |
| 3 års förändring | 121.94% |
| 5 års förändring | -32.89% |
| Förändring sedan börsintroduktionen | -47.56% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • May 19
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology to reflect updated views on fair value at $5.00. This change is accompanied by revised assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple.Analysartikel • May 15
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) earnings announcement last week didn't impress shareholders. However, our...Analysartikel • May 11
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) came out with a strong set of first-quarter numbers that could...Uppdatering av berättelse • Apr 28
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.Recent updates
Uppdatering av berättelse • May 19
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology to reflect updated views on fair value at $5.00. This change is accompanied by revised assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple.Analysartikel • May 15
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) earnings announcement last week didn't impress shareholders. However, our...Analysartikel • May 11
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) came out with a strong set of first-quarter numbers that could...Uppdatering av berättelse • Apr 28
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.Uppdatering av berättelse • Apr 11
PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing
Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).Uppdatering av berättelse • Mar 28
PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing
Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).Uppdatering av berättelse • Mar 13
PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook
Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.Uppdatering av berättelse • Feb 26
PBYI: Index Addition And Refined Assumptions Will Still Limit Upside Potential
Analysts have adjusted their price target on Puma Biotechnology to reflect an updated fair value of $5.00, a slightly lower discount rate of 7.25%, almost unchanged revenue growth at about 97%, a stable profit margin near 11.02%, and a marginally different future P/E of roughly 13.33x, indicating a largely intact valuation framework with only fine tuning to their assumptions. What's in the News Puma Biotechnology, Inc.Uppdatering av berättelse • Feb 11
PBYI: Index Inclusion And Higher Multiple Will Likely Fail To Support Upside
Analysts have raised their price target on Puma Biotechnology to $5.00 from $3.50, citing updates to fair value estimates, discount rate assumptions, and expected future P/E levels. What's in the News Puma Biotechnology, Inc.Uppdatering av berättelse • Jan 26
PBYI: Higher 2025 Guidance And Index Addition Will Not Sustain Current Optimism
Analysts have slightly adjusted their price target on Puma Biotechnology, citing modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these changes translate into a small refinement in estimated fair value rather than a major reset in outlook.
Uppdatering av berättelse • Jan 12
PBYI: Higher 2025 Guidance And Index Inclusion Will Still Look Overpriced
Analysts have lifted their price targets on Puma Biotechnology, citing updates to their models that reflect a fair value estimate of $5.00, adjusted discount rates, revised revenue growth assumptions of about 1% instead of a 3% decline, higher projected profit margins of around 10% compared with about 3%, and a lower assumed future P/E multiple near 14 versus about 37. What's in the News Puma Biotechnology, Inc.Uppdatering av berättelse • Dec 26
PBYI: Raised 2025 Guidance Will Still Fail To Support Current Optimism
Analysts have modestly trimmed their price target on Puma Biotechnology to reflect a slightly lower future earnings multiple, even as estimates for fair value and long term growth remain largely unchanged. What's in the News Puma Biotechnology has been added to the NASDAQ Biotechnology Index, increasing its visibility among biotech-focused investors (index announcement).Uppdatering av berättelse • Dec 12
PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism
Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook. What's in the News Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).Analysartikel • Dec 09
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Uppdatering av berättelse • Nov 27
PBYI: Rising Discount Rate Will Undermine Earnings Momentum In 2025
Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.Analysartikel • Nov 13
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
The market shrugged off Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) solid earnings report. We think that investors might...Seeking Alpha • Nov 10
Puma Biotechnology: Step By Step In Making A Transition
Summary Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise. Read the full article on Seeking AlphaUppdatering av berättelse • Nov 09
PBYI: Rising Discount Rate And Weak Revenue Outlook Will Pressure Earnings
Analysts have raised their price target for Puma Biotechnology from $3.00 to $3.50, citing improved revenue growth projections and stronger expected profit margins. What's in the News Puma Biotechnology issued new earnings guidance for the fourth quarter of 2025, projecting total revenue between $67 million and $70 million, and net income between $9 million and $11 million (Key Developments).Analysartikel • Oct 18
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have continued their recent momentum with a 26% gain in the last month...Analysartikel • Sep 11
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Aug 12
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
NasdaqGS:PBYI 1 Year Share Price vs Fair Value Explore Puma Biotechnology's Fair Values from the Community and select...Analysartikel • Aug 09
We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • May 20
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shareholders have had their patience rewarded with a 25% share price jump in...Seeking Alpha • Apr 11
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Summary Initiate coverage of Puma Biotechnology with a Hold rating due to limited near-term upside, competitive landscape, and uncertain pipeline outlook. NERLYNX adoption is hindered by side effects and competition, while alisertib is still in early development with modest expectations. Puma's cash runway may extend several years, but that could change with faltering revenues for NERLYNX, new drug additions, or other unforeseen pipeline developments. Legal issues and competitive pressures contribute to the cautious outlook, with no clear signs of growth or turnaround. Read the full article on Seeking AlphaAnalysartikel • Mar 10
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have had a really impressive month, gaining 26% after a shaky period...
Ny berättelse • Feb 09
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.Analysartikel • Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Puma Biotechnology, Inc. ( NASDAQ:PBYI ) is...Seeking Alpha • Dec 16
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Summary Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain. Despite market skepticism, I maintain a "Buy" sentiment due to PBYI's favorable financial status and potential growth from alisertib. Read the full article on Seeking AlphaAnalysartikel • Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
When companies post strong earnings, the stock generally performs well, just like Puma Biotechnology, Inc.'s...Analysartikel • Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 26% in...Analysartikel • Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 25% in...Analysartikel • Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Aktieägarnas avkastning
| PBYI | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 2.3% | 1.2% | 1.1% |
| 1Y | 118.9% | 34.6% | 28.7% |
Avkastning vs industri: PBYI översteg US Biotechs branschen som gav 34.6 % under det senaste året.
Avkastning vs Marknaden: PBYI översteg US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| PBYI volatility | |
|---|---|
| PBYI Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: PBYI har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PBYI s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2010 | 179 | Alan Auerbach | www.pumabiotechnology.com |
Puma Biotechnology, Inc. är ett biofarmaceutiskt företag som fokuserar på utveckling och kommersialisering av produkter för att förbättra cancervården i USA och internationellt. Företaget erbjuder NERLYNX, en oral version av neratinib som används för att behandla vuxna patienter med HER2-överuttryckt/förstärkt bröstcancer i tidigt stadium samt avancerad eller metastaserad HER2-positiv bröstcancer i kombination med capecitabin. Företaget utvecklar också alisertib, en småmolekylär hämmare av aurora kinase A för behandling av hormonreceptorpositiv bröstcancer, trippelnegativ bröstcancer, småcellig lungcancer samt huvud- och halscancer.
Puma Biotechnology, Inc. Sammanfattning av grunderna
| PBYI grundläggande statistik | |
|---|---|
| Börsvärde | US$360.37m |
| Vinst(TTM) | US$24.38m |
| Intäkter(TTM) | US$227.18m |
14.8x
P/E-förhållande1.6x
P/S-förhållandeÄr PBYI övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PBYI resultaträkning (TTM) | |
|---|---|
| Intäkter | US$227.18m |
| Kostnad för intäkter | US$58.03m |
| Bruttovinst | US$169.15m |
| Övriga kostnader | US$144.77m |
| Intäkter | US$24.38m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.48 |
| Bruttomarginal | 74.46% |
| Nettovinstmarginal | 10.73% |
| Skuld/egenkapitalförhållande | 8.8% |
Hur har PBYI utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 13:30 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Puma Biotechnology, Inc. bevakas av 13 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Paul Choi | Goldman Sachs |